about   CII home   shop   checkout


Day 1
Day 2
PDF Download   
Hotel & Travel 
Sponsor & Exhibits
Press Pass 
Request Brochure 

Co-Located with
Co-Located with

Pharma Circle





Frost Sullivan

Bio-IT World 

Biocentury logo

Business Monitor

Pharma Healthcare Insight

RD Directions





CHI's Combination Drug Therapies Conference

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

Conference Highlights:

  • Determining the Commercial Scope for Combination Therapies in Particular Therapeutic Areas
  • Achieving Innovative Line Extension and Life-Cycle Management (LCM) Strategies
  • Intellectual Property Leveraging, Licensing, and Protection
  • Overcoming Development and Formulation Challenges of Combination Therapies
  • Emerging Therapeutic Areas for Combinations: Performance to Date and Future Prospects
  • Understanding Regulatory Hurdles and Variation in International Acceptance

Fixed-Dose and Co-Packaged Combinations provide novel business opportunities for companies to leverage their existing portfolio of products and intellectual property in addition to providing avenues for strategic partnership with other companies. However, they also offer unique development, regulatory, and commercial challenges. This conference will focus on the practical interplay between combination therapy forefront research, development challenges, and commercial and partnering strategies, as well as the implications for successful market realization.

Distinguished Faculty

John Ansell, MBA, President, John Ansell Consultancy

Neil Carragher, Ph.D., Principal Scientist, Advanced Science & Technology Lab, AstraZeneca

Rich DiCicco, President, Technology Catalysts International

Timothy R. Franson, M.D., Senior Vice President, B&D Consulting, former Vice President, Global Regulatory Affairs, Eli Lilly & Co.

Shabeer Hussain, Programme Leader, Pharmaceutical and Biotechnology, Healthcare Group, Frost & Sullivan

Venkat Jarugula, Ph.D., Section Head, Clinical PK/PD, Translational Sciences, Novartis Institute of Biomedical Research

Mak Jawadekar, Ph.D., Director, Portfolio Management & Analytics (PMA), Worldwide BioPharmaceutical Businesses, Pfizer, Inc.

Anil Kane, Ph.D., MBA, Senior Director, Pharmaceutical Technical Affairs-NA, Pharmaceutical Development Services, Patheon Inc.
Dennis Kvesic, Director of Marketing, Bayer HealthCare

K. George Mooney, Ph.D., President, Drug Development Integration, KGM Pharma Consulting LLC; former Vice President, Exploratory Development & Pharmaceutical Sciences, Pfizer, Inc.

Hermann Mucke, Ph.D., Founder and Principal, H.M. Pharma Consultancy

Bilikallahalli Muralidhara, Ph.D., Principal Scientist, Pharmaceutical R&D, Global Biologics, Pfizer, Inc.

Aris Persidis, Ph.D., President, Biovista, Inc.
Tina Sampalis, M.D., President, Acasti Pharma, Inc.

Efraim Shek, Ph.D., Senior Vice President, R&D, Ada mas Pharmaceuticals, Inc.

Gangadhar Sunkara, Ph.D., MBA, Director, Translational Sciences (TS), Novartis Institutes for Biomedical Research

Ramana Sonty, MBBS, Ph.D., Director, Neuroscience Project Management, Wyeth Pharmaceuticals

Grant R. Zimmermann, Ph.D., Vice President, Discovery Sciences & Technology, CombinatoRx Incorporated

Alex Zisson, Venture Partner, Thomas, McNerney & Partners

Who should attend:

Executives, Managers and Project Leaders from:

  • Commercial and Legal
  • Corporate Development and Strategy
  • Business Development and Marketing
  • Licensing and Alliance
  • Clinical Pharmacology
  • Formulation Development
  • Drug Regulatory Affairs
  • Clinical Development
  • Portfolio and Project Management
  • Life Cycle Management

Download Conference & Course Catalog

CHI Catalog Cover